search
Back to results

Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial

Primary Purpose

Pregnancy Complications

Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Progesterone
Polyethylene glycol&hydrogenated vegetable oil.
Sponsored by
Stanford University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pregnancy Complications

Eligibility Criteria

18 Years - 55 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:1. Pregnant women with arrested preterm labor between 24+0 to 33+6 weeks pregnant.

2. Intact membranes 3. Singleton pregnancy 4. Greater than or equal to 18 years of age 5. Cervical dilation less than or equal to 4cm Exclusion Criteria:1. Any contraindication to on-going pregnancy 2. Placental abruption 3. Placenta previa 4. Lethal fetal anomalies 5. Premature rupture of membranes 6. Multiple gestation 7. Less than 18 years old 8. Known allergy to any component of the study medication or placebo 9. Severe maternal medical illness

Sites / Locations

  • Stanford University School of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Progesterone

Polyethylene glycol&hydrogenated vegetable oil

Arm Description

Progesterone 400mg per vagina qhs.

Polyethylene glycol&hydrogenated vegetable oil per vagina

Outcomes

Primary Outcome Measures

Reduction in Delivery Rate Prior to 37 Weeks Gestation
Reduction in delivery rate prior to 37 weeks gestation (preterm birth).

Secondary Outcome Measures

Maternal Chorioamnionitis
Maternal Anticipated Adverse Medication Reaction
Birthweight
Newborn birthweight in grams
Neonatal Intensive Care Unit (NICU) Admission
Neonatal Morbidity
Neonatal Mortality
Neonatal Congenital Abnormalities
Number of Days Delay of Delivery
Number of days from intervention to delivery

Full Information

First Posted
July 22, 2009
Last Updated
February 7, 2017
Sponsor
Stanford University
search

1. Study Identification

Unique Protocol Identification Number
NCT00946088
Brief Title
Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial
Official Title
Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Terminated
Why Stopped
lower than expected enrollment
Study Start Date
October 2009 (undefined)
Primary Completion Date
February 2013 (Actual)
Study Completion Date
March 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Stanford University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Preterm delivery is the most common cause of infant morbidity and mortality in the United States. Some women have episodes of preterm labor during their pregnancy which can be temporarily stopped. These women, however, are at high risk for delivering before term. At this time, we do not have sufficient evidence to use any medication to help prevent these women from delivering early. Recently, preliminary studies have shown that progesterone may help prevent some women at high risk for preterm delivery from delivering early. Our study will investigate whether progesterone can help this specific group of women, women with arrested preterm labor, deliver healthy infants at term.
Detailed Description
The purpose of this study is to test the efficacy of progesterone in prolonging human pregnancies complicated by arrested preterm labor. Animal labor has not been shown to be equivalent to human labor and would not be an appropriate substitute for this study. In addition, this medication has been previously used in pregnant women without any evidence of significant harm to the mother or fetus. Women will be approached for enrollment in the study during their hospitalization for preterm labor. If they choose to enroll, they will have weekly MD visits at the obstetrical clinic, daily use of vaginal progesterone that will be self administered, and routine obstetric care at the time of recurrent labor and delivery. The daily progesterone is not a part of routine care for these patients. In addition, we will ask patients to fill out a written questionaire one week after starting the medication to describe any subjective symptoms that may be associated with this medication. Finally, we will assess the peripheral levels of progesterone with a blood draw prior to starting the mediation, one week after starting the medication, and at the time of recurrent pre-term labor or delivery. The first two of these blood draws will be in addition to the standard treatment. The final blood draw will involve collecting an extra sample at a time when the participant would normally have blood drawn as a part of routine care.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pregnancy Complications

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
7 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Progesterone
Arm Type
Active Comparator
Arm Description
Progesterone 400mg per vagina qhs.
Arm Title
Polyethylene glycol&hydrogenated vegetable oil
Arm Type
Placebo Comparator
Arm Description
Polyethylene glycol&hydrogenated vegetable oil per vagina
Intervention Type
Drug
Intervention Name(s)
Progesterone
Intervention Description
Progesterone 400 mg per vagina qhs.
Intervention Type
Drug
Intervention Name(s)
Polyethylene glycol&hydrogenated vegetable oil.
Intervention Description
Placebo Comparator: Polyethylene glycol 400 distearate & hydrogenated vegetable oil per vagina qhs.
Primary Outcome Measure Information:
Title
Reduction in Delivery Rate Prior to 37 Weeks Gestation
Description
Reduction in delivery rate prior to 37 weeks gestation (preterm birth).
Time Frame
Up to 37 weeks of gestation
Secondary Outcome Measure Information:
Title
Maternal Chorioamnionitis
Time Frame
Up to maternal hospital discharge
Title
Maternal Anticipated Adverse Medication Reaction
Time Frame
Up to the maternal discharge from delivery hospitalization
Title
Birthweight
Description
Newborn birthweight in grams
Time Frame
At the time of newborn birth
Title
Neonatal Intensive Care Unit (NICU) Admission
Time Frame
At time of neonatal discharge
Title
Neonatal Morbidity
Time Frame
Up to 28 days after neonatal birth
Title
Neonatal Mortality
Time Frame
Up to 28 days after neonatal birth
Title
Neonatal Congenital Abnormalities
Time Frame
Up to the time of neonatal discharge from the delivery hospital
Title
Number of Days Delay of Delivery
Description
Number of days from intervention to delivery
Time Frame
Up to the time of delivery

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:1. Pregnant women with arrested preterm labor between 24+0 to 33+6 weeks pregnant. 2. Intact membranes 3. Singleton pregnancy 4. Greater than or equal to 18 years of age 5. Cervical dilation less than or equal to 4cm Exclusion Criteria:1. Any contraindication to on-going pregnancy 2. Placental abruption 3. Placenta previa 4. Lethal fetal anomalies 5. Premature rupture of membranes 6. Multiple gestation 7. Less than 18 years old 8. Known allergy to any component of the study medication or placebo 9. Severe maternal medical illness
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Deirdre Judith Lyell, MD
Organizational Affiliation
Stanford University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stanford University School of Medicine
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial

We'll reach out to this number within 24 hrs